Eko Health Secures $41 Million to Expand AI-Driven Heart and Lung Disease Detection

Thursday, June 06, 2024

Eko Health, a pioneer in using artificial intelligence to detect heart and lung diseases early, announced it raised $41 million in Series D financing.

The funding, with contributions from ARTIS Ventures, Highland Capital Partners, NTTVC, and Questa Capital, aims to expand access to the company's early disease detection platform in the U.S. and globally.

The funding follows recent milestones, including FDA clearances for its structural heart murmur and low ejection fraction (Low EF) detection algorithms.

Eko's murmur detection algorithm, validated in a Massachusetts General Hospital study, doubled identification rates of structural heart murmurs compared to conventional methods in primary care. The low EF detection algorithm, developed with Mayo Clinic, significantly improved the identification of heart failure with reduced ejection fraction in GP clinics, as demonstrated in an Imperial College London study.

The company's mission to provide universal access to expert-level cardiac and pulmonary disease detection. Landgraf compared Eko's impact to that of Ring, transforming commonplace medical tools into a powerful early disease detection platform.

Cardiovascular and pulmonary diseases are leading causes of death globally, underscoring the need for early detection. Eko aims to address this gap by integrating advanced detection capabilities into routine physical exams, from primary care in the U.S. to maternal-fetal health exams in Nigeria.

Eko Health and Partner at ARTIS Ventures, highlighted the personal significance of the company's mission, having lost a parent to undetected heart disease. Bailey praised Eko's dedication to saving lives through its early detection platform.

With investments from Double Point Ventures, EDBI, and LG Technology Ventures, Eko plans to expand its presence in the U.S. and international markets. With regulatory clearances and fresh funding,.

Eko aims to extend access to its AI-enabled disease detection platform, empowering healthcare professionals to improve patient outcomes globally.


Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital Congress